Document Detail

Adenosine dose should be less when administered through a central line.
MedLine Citation:
PMID:  11858927     Owner:  NLM     Status:  MEDLINE    
A patient with a port-a-cath was given 12 mg of adenosine for paroxysmal supraventricular tachycardia (PSVT), resulting in prolonged (13 s) bradycardia and severe side effects. When the same patient presented 2 weeks later for recurrent PSVT, only 3 mg of adenosine was needed to terminate the episode, without the patient experiencing prolonged bradycardia or severe side effects. The literature suggests that for patients with central venous catheters, a lower dose of adenosine should be used to terminate PSVT.
Michael Chang; Keith Wrenn
Related Documents :
23311457 - Immune cells after prolonged natalizumab therapy: implications for effectiveness and sa...
23079047 - Iron deposition in the precentral grey matter in patients with multiple sclerosis: a qu...
6777317 - Tooth extractions and sick sinus syndrome.
6173857 - Atrioventricular dissociation during paroxysmal junctional tachycardia.
2772977 - Atheromatous pseudo-occlusion of the internal carotid artery.
14581707 - Evaluation of two calcium alginate dressings in the management of venous ulcers.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Journal of emergency medicine     Volume:  22     ISSN:  0736-4679     ISO Abbreviation:  J Emerg Med     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-02-22     Completed Date:  2002-04-16     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8412174     Medline TA:  J Emerg Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  195-8     Citation Subset:  IM    
Department of Emergency Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-4700, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine / administration & dosage*,  therapeutic use
Anti-Arrhythmia Agents / administration & dosage*,  therapeutic use
Catheterization, Central Venous / instrumentation
Tachycardia, Supraventricular / drug therapy*
Treatment Outcome
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 58-61-7/Adenosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Electrocardiographic manifestations: right ventricular infarction.
Next Document:  PTEN: The down side of PI 3-kinase signalling.